Tags

Type your tag names separated by a space and hit enter

Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation.
Arch Neurol. 2011 Dec; 68(12):1550-6.AN

Abstract

OBJECTIVE

To assess the 10-year motor outcome of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with Parkinson disease (PD).

DESIGN

Patients with PD with bilateral STN-DBS were assessed according to the Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease protocol and videotaped at baseline and 1, 5, and 10 years after surgery. An independent rater blinded to stimulation and medication condition scored the 10-year video assessments.

SETTING

Movement Disorders Centre, Toronto Western Hospital, University Health Network, University of Toronto.

PATIENTS

Eighteen patients with advanced PD and 10-year follow-up of STN-DBS.

INTERVENTION

Bilateral STN-DBS surgery.

MAIN OUTCOME MEASURES

The primary outcome was the change in blinded Unified Parkinson's Disease Rating Scale (UPDRS) motor scores/subscores between the no medication/stimulation condition vs the no medication/no stimulation condition at 10 years. Secondary outcomes were the changes in blinded UPDRS motor scores between the medication/no stimulation and medication/stimulation conditions, UPDRS II scores, UPDRS IV dyskinesia and motor fluctuations scores, and anti-PD medication dose (levodopa equivalent daily dose) at different points.

RESULTS

In the 18 patients available for follow-up at 10 years, STN-DBS still significantly improved the UPDRS total motor score (P = .007) and resting and action tremor (P < .01 and P = .02, respectively) and bradykinesia (P = .01) subscores. The UPDRS II scores in the medication and no medication conditions, UPDRS IV dyskinesia and motor fluctuations scores, and the levodopa equivalent daily dose were also significantly reduced compared with baseline. Axial signs showed the most progressive decline in stimulation and levodopa response over the years.

CONCLUSION

This class III study provides evidence that stimulation-induced motor improvement was sustained overall at 10 years, although part of the initial benefit wore off mainly because of progressive loss of benefit on axial signs over time.

Authors+Show Affiliations

Clinica Neurologica, Università degli Studi di Perugia, Perugia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

21825213

Citation

Castrioto, Anna, et al. "Ten-year Outcome of Subthalamic Stimulation in Parkinson Disease: a Blinded Evaluation." Archives of Neurology, vol. 68, no. 12, 2011, pp. 1550-6.
Castrioto A, Lozano AM, Poon YY, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol. 2011;68(12):1550-6.
Castrioto, A., Lozano, A. M., Poon, Y. Y., Lang, A. E., Fallis, M., & Moro, E. (2011). Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Archives of Neurology, 68(12), 1550-6. https://doi.org/10.1001/archneurol.2011.182
Castrioto A, et al. Ten-year Outcome of Subthalamic Stimulation in Parkinson Disease: a Blinded Evaluation. Arch Neurol. 2011;68(12):1550-6. PubMed PMID: 21825213.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. AU - Castrioto,Anna, AU - Lozano,Andres M, AU - Poon,Yu-Yan, AU - Lang,Anthony E, AU - Fallis,Melanie, AU - Moro,Elena, Y1 - 2011/08/08/ PY - 2011/8/10/entrez PY - 2011/8/10/pubmed PY - 2012/2/3/medline SP - 1550 EP - 6 JF - Archives of neurology JO - Arch Neurol VL - 68 IS - 12 N2 - OBJECTIVE: To assess the 10-year motor outcome of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with Parkinson disease (PD). DESIGN: Patients with PD with bilateral STN-DBS were assessed according to the Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease protocol and videotaped at baseline and 1, 5, and 10 years after surgery. An independent rater blinded to stimulation and medication condition scored the 10-year video assessments. SETTING: Movement Disorders Centre, Toronto Western Hospital, University Health Network, University of Toronto. PATIENTS: Eighteen patients with advanced PD and 10-year follow-up of STN-DBS. INTERVENTION: Bilateral STN-DBS surgery. MAIN OUTCOME MEASURES: The primary outcome was the change in blinded Unified Parkinson's Disease Rating Scale (UPDRS) motor scores/subscores between the no medication/stimulation condition vs the no medication/no stimulation condition at 10 years. Secondary outcomes were the changes in blinded UPDRS motor scores between the medication/no stimulation and medication/stimulation conditions, UPDRS II scores, UPDRS IV dyskinesia and motor fluctuations scores, and anti-PD medication dose (levodopa equivalent daily dose) at different points. RESULTS: In the 18 patients available for follow-up at 10 years, STN-DBS still significantly improved the UPDRS total motor score (P = .007) and resting and action tremor (P < .01 and P = .02, respectively) and bradykinesia (P = .01) subscores. The UPDRS II scores in the medication and no medication conditions, UPDRS IV dyskinesia and motor fluctuations scores, and the levodopa equivalent daily dose were also significantly reduced compared with baseline. Axial signs showed the most progressive decline in stimulation and levodopa response over the years. CONCLUSION: This class III study provides evidence that stimulation-induced motor improvement was sustained overall at 10 years, although part of the initial benefit wore off mainly because of progressive loss of benefit on axial signs over time. SN - 1538-3687 UR - https://www.unboundmedicine.com/medline/citation/21825213/Ten_year_outcome_of_subthalamic_stimulation_in_Parkinson_disease:_a_blinded_evaluation_ L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneurol.2011.182 DB - PRIME DP - Unbound Medicine ER -